Iranian Red Crescent Medical Journal

Published by: Kowsar

The Effectiveness of Gemfibrozil on Nicotine Dependence, Smoking Cessation, and its Symptom Among Smokers: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Fatemeh Sadat Ghoreishi 1 , Mohammadreza Davoudi 2 , Fatemeh Assarian 1 and Maryam Shahriyari 3 , *
Authors Information
1 Department of Psychiatry, Kashan University of Medical Sciences, Kashan, Iran
2 Department of Clinical Psychology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
3 Department of Psychiatry, School of Medicine, Kashan University of Medical Science, Kashan, Iran
Article information
  • Iranian Red Crescent Medical Journal: January 31, 2019, 21 (1); e83294
  • Published Online: February 3, 2019
  • Article Type: Research Article
  • Received: August 13, 2018
  • Revised: November 9, 2018
  • Accepted: November 11, 2018
  • DOI: 10.5812/ircmj.83294

To Cite: Ghoreishi F S, Davoudi M, Assarian F, Shahriyari M. The Effectiveness of Gemfibrozil on Nicotine Dependence, Smoking Cessation, and its Symptom Among Smokers: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Iran Red Crescent Med J. 2019 ; 21(1):e83294. doi: 10.5812/ircmj.83294.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Zainul Z. Dark nights behind the white clouds - risks of tobacco smoking on human health besides the oral health and malignancy. EXCLI J. 2011;10:69-84. [PubMed: 29033703]. [PubMed Central: PMC5611642].
  • 2. Khalil MAM, Tan J, Khamis S, Khalil MA, Azmat R, Ullah AR. Cigarette smoking and its hazards in kidney transplantation. Adv Med. 2017;2017:6213814. doi: 10.1155/2017/6213814. [PubMed: 28819637]. [PubMed Central: PMC5551477].
  • 3. Primack BA, Carroll MV, Weiss PM, Shihadeh AL, Shensa A, Farley ST, et al. Systematic review and meta-analysis of inhaled toxicants from waterpipe and cigarette smoking. Public Health Rep. 2016;131(1):76-85. doi: 10.1177/003335491613100114. [PubMed: 26843673]. [PubMed Central: PMC4716475].
  • 4. Valdes-Salgado R, Reynales-Shiguematsu LM, Lazcano-Ponce EC, Hernandez-Avila M. Susceptibility to smoking among adolescents and its implications for Mexico's tobacco control programs. Analysis of the global youth tobacco survey 2003-2004 and 2006-2007. Int J Environ Res Public Health. 2009;6(3):1254-67. doi: 10.3390/ijerph6031254. [PubMed: 19440444]. [PubMed Central: PMC2672381].
  • 5. Pechmann C. Does antismoking advertising combat underage smoking? A review of past practices and research. In: Goldberg ME, Fishbein M, Middlestadt SE, editors. Social marketing: Theoretical and practical perspectives. Psychology Press; 2018. p. 189-216.
  • 6. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: A brief review of recent epidemiological evidence. Lung Cancer. 2004;45 Suppl 2:S3-9. doi: 10.1016/j.lungcan.2004.07.998. [PubMed: 15552776].
  • 7. Moynihan JA, Chapman BP, Klorman R, Krasner MS, Duberstein PR, Brown KW, et al. Mindfulness-based stress reduction for older adults: Effects on executive function, frontal alpha asymmetry and immune function. Neuropsychobiology. 2013;68(1):34-43. doi: 10.1159/000350949. [PubMed: 23774986]. [PubMed Central: PMC3831656].
  • 8. de Jong M, Lazar SW, Hug K, Mehling WE, Holzel BK, Sack AT, et al. Effects of mindfulness-based cognitive therapy on body awareness in patients with chronic pain and comorbid depression. Front Psychol. 2016;7:967. doi: 10.3389/fpsyg.2016.00967. [PubMed: 27445929]. [PubMed Central: PMC4927571].
  • 9. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: A systematic review and meta-analysis. Lancet Respir Med. 2016;4(2):116-28. doi: 10.1016/S2213-2600(15)00521-4. [PubMed: 26776875]. [PubMed Central: PMC4752870].
  • 10. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017;3. CD001292. doi: 10.1002/14651858.CD001292.pub3. [PubMed: 28361496].
  • 11. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry. 2011;69(7):633-41. doi: 10.1016/j.biopsych.2010.07.009. [PubMed: 20801430]. [PubMed Central: PMC2994947].
  • 12. Melis M, Pistis M. Hub and switches: Endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3276-85. doi: 10.1098/rstb.2011.0383. [PubMed: 23108546]. [PubMed Central: PMC3481525].
  • 13. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70(4):439-46. doi: 10.1016/S0091-3057(01)00652-9. [PubMed: 11796143].
  • 14. Benowitz NL. Neurobiology of nicotine addiction: Implications for smoking cessation treatment. Am J Med. 2008;121(4 Suppl 1):S3-10. doi: 10.1016/j.amjmed.2008.01.015. [PubMed: 18342164].
  • 15. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58(4):726-41. doi: 10.1124/pr.58.4.5. [PubMed: 17132851].
  • 16. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):56-63. doi: 10.1001/jama.296.1.56. [PubMed: 16820547].
  • 17. Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, et al. Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology. 2015;40(9):2185-97. doi: 10.1038/npp.2015.62. [PubMed: 25754762]. [PubMed Central: PMC4613608].
  • 18. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: Haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet. 2006;120(4):581-8. doi: 10.1007/s00439-006-0250-x. [PubMed: 16972078].
  • 19. Sloan ME, Gowin JL, Yan J, Schwandt ML, Spagnolo PA, Sun H, et al. Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant. Addict Biol. 2018;23(1):474-84. doi: 10.1111/adb.12491. [PubMed: 28150397]. [PubMed Central: PMC5538894].
  • 20. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A. 2002;99(12):8394-9. doi: 10.1073/pnas.082235799. [PubMed: 12060782]. [PubMed Central: PMC123078].
  • 21. Zehsaz F, Abbasi Soltani H, Hazrati R, Farhangi N, Monfaredan A, Ghahramani M. Association between the PPARa and PPARGCA gene variations and physical performance in non-trained male adolescents. Mol Biol Rep. 2018;45(6):2545-53. doi: 10.1007/s11033-018-4422-2.
  • 22. Tang Y, M. Vanlandingham M , Wu Y, Beland FA, Olson GR, Fang JL. Role of peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARalpha-mediated species differences in triclosan-induced liver toxicity. Arch Toxicol. 2018;92(11):3391-402. doi: 10.1007/s00204-018-2308-7. [PubMed: 30238133].
  • 23. Gendy MNS, Di Ciano P, Kowalczyk WJ, Barrett SP, George TP, Heishman S, et al. Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARalpha agonist) in smokers. PLoS One. 2018;13(9). e0201512. doi: 10.1371/journal.pone.0201512. [PubMed: 30260990]. [PubMed Central: PMC6160014].
  • 24. Zambrana-Infantes E, Rosell Del Valle C, Ladron de Guevara-Miranda D, Galeano P, Castilla-Ortega E, Rodriguez De Fonseca F, et al. Palmitoylethanolamide attenuates cocaine-induced behavioral sensitization and conditioned place preference in mice. Pharmacol Biochem Behav. 2018;166:1-12. doi: 10.1016/j.pbb.2018.01.002. [PubMed: 29337083].
  • 25. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421-4. doi: 10.1038/35013000. [PubMed: 10839530].
  • 26. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48(1):1-26. doi: 10.1016/j.plipres.2008.08.001. [PubMed: 18824034].
  • 27. Perkins KA, Karelitz JL, Michael VC, Fromuth M, Conklin CA, Chengappa KNR, et al. Initial evaluation of fenofibrate for efficacy in aiding smoking abstinence. Nicotine Tob Res. 2015:ntv085. doi: 10.1093/ntr/ntv085.
  • 28. Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, et al. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: A controlled comparison. Support Care Cancer. 2016;24(5):2201-7. doi: 10.1007/s00520-015-3016-y. [PubMed: 26563183]. [PubMed Central: PMC4805468].
  • 29. Paulus DJ, Langdon KJ, Wetter DW, Zvolensky MJ. Dispositional mindful attention in relation to negative affect, tobacco withdrawal, and expired carbon monoxide on and after quit day. J Addict Med. 2018;12(1):40-4. doi: 10.1097/ADM.0000000000000361. [PubMed: 28922195]. [PubMed Central: PMC5786492].
  • 30. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The fagerstrom test for nicotine dependence: A revision of the fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x. [PubMed: 1932883].
  • 31. Jarvis MJ, Russell MA, Saloojee Y. Expired air carbon monoxide: A simple breath test of tobacco smoke intake. Br Med J. 1980;281(6238):484-5. doi: 10.1136/bmj.281.6238.484. [PubMed: 7427332]. [PubMed Central: PMC1713376].
  • 32. McBride WJ, Murphy JM, Ikemoto S. Localization of brain reinforcement mechanisms: Intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res. 1999;101(2):129-52. doi: 10.1016/S0166-4328(99)00022-4. [PubMed: 10372570].
  • 33. Quezada-Berumen L, Gonzalez-Ramirez MT, Cebolla A, Soler J, Garcia-Campayo J. Body awareness and mindfulness: Validation of the Spanish version of the scale of body connection. Actas Esp Psiquiatr. 2014;42(2):57-67. [PubMed: 24715363].
  • 34. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195-202. doi: 10.1056/NEJM199710233371703. [PubMed: 9337378].
  • 35. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5):522-33. doi: 10.1001/jamapsychiatry.2013.678. [PubMed: 23536105]. [PubMed Central: PMC4128024].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments